Can-Fite BioPharma Ltd. Overview
Pro stress-test →Can-Fite BioPharma is a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is advancing multiple candidates through clinical development with particular focus on rare cancers and liver disease, addressing multi-billion-dollar unmet medical needs.
Strategic Profile
Pro stress-test →The company is currently enrolling patients in a pivotal Phase III clinical study evaluating Namodenoson for advanced hepatocellular carcinoma in patients with Child-Pugh B7 liver function, a patient population with no approved therapies currently available. The company's lead drug candidate Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. The company has orphan drug and fast-track designations from the FDA for multiple programs.
Competitive Landscape
Pro stress-test →Can-Fite competes in the oncology and immunology spaces. Competitors in liver cancer include companies developing other HCC treatments, though Can-Fite's focus on the Child-Pugh B7 patient population addresses an underserved market. In psoriasis and inflammatory disease, competition includes established players and other biotech firms. The company's advantage lies in its novel A3 adenosine receptor agonist mechanism and clinical proof-of-concept in multiple indications.
Industry Context
Can-Fite BioPharma Ltd. operates in Biopharmaceutical / Clinical-stage Oncology and Immunology.
Key facts
Founded: 1994 · Headquarters: Ramat Gan, Israel